{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:13Z","timestamp":1761094153867,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":2504,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.bbmt.2008.01.007","type":"journal-article","created":{"date-parts":[[2008,5,18]],"date-time":"2008-05-18T04:08:08Z","timestamp":1211083688000},"page":"709-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved"],"prefix":"10.1016","volume":"14","author":[{"given":"Nicolas","family":"Novitzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valda","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Mcdonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2008.01.007_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia","volume":"332","author":"Zittoun","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.bbmt.2008.01.007_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.1994.tb03253.x","article-title":"Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia: risk factors and clinical outcome","volume":"86","author":"Weisdorf","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.7326\/0003-4819-108-6-806","article-title":"Bone marrow transplantation for chronic myelogenous leukemia in chronic phase","volume":"108","author":"Goldman","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2008.01.007_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","article-title":"Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Van Rhee","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib5","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/0959-8049(93)90287-P","article-title":"Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukaemia patients","volume":"29A","author":"Valls","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2008.01.007_bib6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1046\/j.1365-2141.2002.03532.x","article-title":"Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry","volume":"117","author":"Greinix","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib7","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukaemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic disease","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bmt.1703134","article-title":"Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy","volume":"28","author":"Mohty","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib10","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma following reduced-intensity allogeneic progenitor. An analysis from the Lymphoma Working Group for Blood and Bone Marrow Transplantation","volume":"13","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0140-6736(84)92564-9","article-title":"Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)","volume":"ii","author":"Waldmann","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2008.01.007_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbmt.2005.01.001","article-title":"What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?","volume":"11","author":"Mohamed","year":"2005","journal-title":"Biol of Blood and Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated 15 by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","article-title":"CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells","volume":"26","author":"Hale","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/14653240310004520","article-title":"Campath-1 Abs \u2018in the bag\u2019 for hematological malignancies: the Cape Town experience","volume":"6","author":"Novitzky","year":"2004","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2008.01.007_bib16","first-page":"403","article-title":"Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome","volume":"2","author":"Keating","year":"1988","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2008.01.007_bib17","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data\u2013based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.1997.15.2.466","article-title":"Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461","volume":"15","author":"Byrd","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007890-199902270-00022","article-title":"Ex vivo depletion of T-cells from BM grafts with CAMPATH 1G in acute leukemia: Graft vs Host disease and Graft vs. Leukemia effect","volume":"67","author":"Novitzky","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2008.01.007_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","article-title":"The ISHAGE guidelines for CD34+ cell determination by flow cytometry","volume":"5","author":"Sutherland","year":"1996","journal-title":"J Hematotherapy"},{"key":"10.1016\/j.bbmt.2008.01.007_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft vs host disease in human recipients of marrow from HLA matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2008.01.007_bib22","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/00007890-200004150-00025","article-title":"Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy","volume":"69","author":"Novitzky","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2008.01.007_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V67.3.770.770","article-title":"Bone marrow transplantation in patients aged 45 years and older","volume":"67","author":"Greenberg","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bmt.1704379","article-title":"Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning: results from the Spanish multicenter prospective trial","volume":"33","author":"Gomez-Nunez","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bbmt.2008.01.007_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: 16 disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2008.01.007_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1083-8791(03)70009-3","article-title":"Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy","volume":"9","author":"Levine","year":"2003","journal-title":"Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood and Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bbmt.2008.01.007_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib30","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1999.17.5.1545","article-title":"Martelli improved outcome with T cell\u2013depleted bone marrow transplantation for acute leukemia","volume":"17","author":"Aversa","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0301-472X(03)00223-6","article-title":"Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection","volume":"31","author":"Canals","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1053\/bbmt.2002.v8.abbmt080656","article-title":"Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants","volume":"8","author":"Bacigalupo","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2008.01.007_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (Cdw 52)","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.bbmt.2008.01.007_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2002-05-1615","volume":"101","author":"Elmaagacli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib35","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2001.19.4.1152","article-title":"CD61 donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors","volume":"19","author":"Soiffer","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib36","first-page":"3996","article-title":"T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities","volume":"95","author":"Champlin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2141.2003.04228.x","article-title":"T-cell depletion with Campath-1H \u2018in the bag\u2019 for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival","volume":"121","author":"Chakrabarti","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2008.01.007_bib38","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders increased after DLI","volume":"100","author":"Perez-Simon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib39","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1182\/blood.V99.12.4357","article-title":"High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath- 1H in delaying immune reconstitution","volume":"99","author":"Chakrabarti","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","article-title":"Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications","volume":"102","author":"Morris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2008.01.007_bib41","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2008.01.007_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u20138 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879108000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:31:27Z","timestamp":1761057087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879108000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1083879108000530"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.01.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2008.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}